for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amneal Pharmaceuticals Inc

AMRX.N

Latest Trade

2.75USD

Change

0.04(+1.48%)

Volume

267,156

Today's Range

2.71

 - 

2.78

52 Week Range

2.27

 - 

19.31

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2.71
Open
2.75
Volume
267,156
3M AVG Volume
35.68
Today's High
2.78
Today's Low
2.71
52 Week High
19.31
52 Week Low
2.27
Shares Out (MIL)
464.11
Market Cap (MIL)
822.53
Forward P/E
8.89
Dividend (Yield %)
--

Latest Developments

More

Amneal Enters Into A Licensing Agreement With Kashiv Biosciences, Llc To Develop And Commercialize K127 For The Treatment Of Myasthenia Gravis

Amneal Announces Launch Of Generic Invega

Amneal Announces Approval Of Generic Version Of Amicar

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Generics and Specialty Pharma. The Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Industry

Biotechnology & Drugs

Contact Info

400 Crossing Blvd Fl 3

+1.908.4096700

https://www.amneal.com/

Executive Leadership

Paul M. Meister

Chairman of the Board

Chirag Patel

President, Co-Chief Executive Officer, Director

Chintu Patel

Co-Chief Executive Officer, Director

Kanwal Pandita

Managing Partner - RAKS

Todd P. Branning

Chief Financial Officer, Senior Vice President

Key Stats

2.77 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.8K

2017

0.8K

2018

1.7K

2019(E)

1.6K
EPS (USD)

2016

1.160

2017

0.630

2018

0.980

2019(E)

0.309
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.48
Price To Book (MRQ)
3.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1,243.97
LT Debt To Equity (MRQ)
1,234.12
Return on Investment (TTM)
-17.45
Return on Equity (TTM)
-13.50

Latest News

Latest News

Amneal cuts forecast as epinephrine shot supply issues linger, shares slump 36%

Shares of Amneal Pharmaceuticals Inc plunged 36% to an all-time low on Wednesday after the generic drugmaker cut its 2019 core earnings forecast due to supply uncertainties related to its epinephrine auto-injectors.

Amneal Pharma slashes core earnings forecast on allergy shot supply issues

Amneal Pharmaceuticals Inc on Wednesday cut its core earnings forecast for the year, citing uncertainty in supply of epinephrine auto-injectors amid a global shortage of the emergency allergy shots, including Mylan NV's EpiPen.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up